Spherical Nucleic Acids Deliver a New Package for Oliognucleotide Therapeutics
SNAs Are a Hopeful First Step in Boosting the Utility of Oligonucleotides to Treat a Variety of Human Diseases
Downstream Issues Still Beset Production
To Protect the Bottom Line, Biomanufacturers Invest in Downstream Purification Technology
GEN Roundup: No Detail Is Too Small in Bioprocess Scaleup
A Change in Scale Can Change Everything
Amid Election Clamor, Research Issues Surface
Sounds of Science Podcast
FDA: Too Restrictive?
In a debate held on May 8, 2013, major thinkers argued over whether or not the FDA is failing its mandate of protecting the public health, as its approval processes can slow the process of bringing new treatments to market. The debate featured a poll asking participants if they agree with the statement “The FDA’s caution is hazardous to our health.” The results: before the debate, 24% were in favor of that statement, 32% were against it, and 44% were undecided; after the debate, 53% were in favor, 38% were against it, and 9% were undecided. Now, we’re asking GEN readers a similar question.